The development of immunotherapy in older adults: New treatments, new toxicities?

Hélissey, Carole; Vicier, Cécile; Champiat, Stéphane

doi:10.1016/j.jgo.2016.05.007

Cited by 89 publications

(61 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thermally mediated cell death within the immediate region is rapid and can create an immediate source of antigen to enhance tumor recognition (34). A rapid response is attractive since clonal evolution can produce ever more aggressive phenotypes, which are resistant to targeted therapeutics (35,36) and immunotherapeutic toxicity can be dose limiting (37).…”

Section: Discussionmentioning

confidence: 99%

Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols

Silvestrini¹,

Ingham²,

Mahakian³

et al. 2017

JCI Insight

111

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols

Silvestrini¹,

Ingham²,

Mahakian³

et al. 2017

JCI Insight

111

View full text Add to dashboard Cite

“…The number of older patients recruited in clinical trials with immunotherapies for cancer is generally low, thus preventing from definitive conclusions about safety and tolerability of these agents (55).…”

Section: Immunotherapymentioning

confidence: 99%

Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments

Tortorella¹,

Vizzielli²,

Fusco³

et al. 2017

Aging and disease

View full text Add to dashboard Cite

Ovarian cancer is the most common cause of death from gynecological cancers in developed countries. It is a common disease of older women at or above 63 years upon diagnosis. Thanks to advance in new treatments, mortality from ovarian cancer has declined in developed countries in the last decade. This decline in mortality rate is unevenly distributed across the age-spectrum. While mortality in younger women has decreased 21.7%, for elderly women it has declined only 2.2%. Even if ovarian cancer is clearly a disease of the elderly, older women are underrepresented in clinical trials, and scant evidence exists for the treatment of women older than 80 years. Moreover, older women are frequently undertreated, receive less chemotherapy and less combination of surgery and chemotherapy, despite the fact that this is considered the optimal treatment modality. This may be mainly due to the lack of evidence and physician’s confidence in the management of elderly women with ovarian cancer. In this review, we focus on the management of older women with ovarian cancer, considering geriatric features tied to this population.

show abstract

“…Indeed, compared with conventional cancer therapies, immunotherapy offers a better safety profile with ,10% of severe toxicities and is therefore an attractive option in older patients. 25,26 Due to the low toxicity prolife, the revolution of immune cancer therapy might especially be of great interest in the older population. Nevertheless, at the moment, there is few evidence of efficacy and tolerance of these drugs in the geriatric population.…”

Section: Future Perspectivesmentioning

confidence: 99%

<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>

Baldini¹,

Champiat²,

Vuagnat³

et al. 2019

OTT

Self Cite

View full text Add to dashboard Cite

Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression ,12 months after neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.

show abstract

The development of immunotherapy in older adults: New treatments, new toxicities?

Cited by 89 publications

References 45 publications

Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols

Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols

Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments

<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>

Contact Info

Product

Resources

About